Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?

Polymyalgia rheumatica (PMR) is a chronic inflammatory disease of unknown aetiology affecting people aged over 50. The hallmark manifestations of PMR are pain and stiffness affecting the neck and shoulder and pelvic girdles. There is no specific laboratory test for the disease, and thus the diagnosis of PMR depends on a combination of clinical symptoms, raised acute phase reactants, the exclusion of other diagnoses and response to glucocorticoids (GCs).1 For classification purposes, a number of criteria have been proposed and the most recent were collectively drawn up by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR).2 Giant cell arteritis (GCA) is a type of vasculitis of large-sized and medium-sized arteries affecting people aged over 50. The disease usually involves aorta, supra-aortic branches and the extracranial branches of the carotid artery. The clinical manifestations include headaches, temporal artery or scalp tenderness, jaw claudication, visual symptoms, constitutional symptoms and PMR manifestations.3 At the time of diagnosis, the most serious consequence of GCA is the occurrence of visual loss in 12–14% of patients.4 Aortic aneurysm or dissection may develop during follow-up and can be potentially life-threatening. The gold standard for the diagnosis of GCA remains temporal artery biopsy (TAB). Approximately 60–80% of TABs show evidence of vasculitis with a mononuclear cell infiltrate, disruption of the internal elastic lamina and multinucleated giant cells, the hallmark of the disease, in ∼50% of patients.5 However, ACR classification criteria were developed in patients who already have evidence of vasculitis and do not take into account the additional value of imaging techniques.6 Indeed, ultrasonography of TAB may reveal a hypoechoic halo sign and is considered to be highly specific for GCA diagnosis despite interobserver and interstudy discrepancies.7 In addition, positron emission tomography (PET) is a valuable …

[1]  M. Dougados,et al.  Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients , 2016, The Journal of Rheumatology.

[2]  S. Reichenbach,et al.  Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.

[3]  F. Galateau-Sallé,et al.  Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). , 2016, La Revue de medecine interne.

[4]  A. Saraux,et al.  Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study , 2016, Annals of the rheumatic diseases.

[5]  Antoine Martin,et al.  Rapid and Sustained Response to Tocilizumab in Patients with Polymyalgia Rheumatica Resistant or Intolerant to Glucocorticoids: A Multicenter Open-label Study , 2016, The Journal of Rheumatology.

[6]  B. Dasgupta,et al.  Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis , 2016, RMD Open.

[7]  T. Takeuchi,et al.  Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases , 2015, RMD Open.

[8]  K. Barraclough,et al.  2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2015, Annals of the rheumatic diseases.

[9]  M. González-Gay,et al.  Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. , 2015, Seminars in arthritis and rheumatism.

[10]  G. Rossi,et al.  Inflamed Temporal Artery: Histologic Findings in 354 Biopsies, With Clinical Correlations , 2014, The American journal of surgical pathology.

[11]  S. Mori,et al.  Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy , 2014, Clinical Rheumatology.

[12]  C. Salvarani,et al.  Update on polymyalgia rheumatica. , 2013, European journal of internal medicine.

[13]  C. Salvarani,et al.  Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. , 2013, Seminars in arthritis and rheumatism.

[14]  S. Unizony,et al.  Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica , 2012, Arthritis care & research.

[15]  B. Bonnotte,et al.  Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. , 2012, Arthritis and rheumatism.

[16]  J. Besancenot,et al.  Efficacy of tocilizumab in refractory giant cell arteritis. , 2012, Joint, bone, spine : revue du rhumatisme.

[17]  A. Iagnocco,et al.  2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2012, Annals of the rheumatic diseases.

[18]  Shaifali Jain,et al.  Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement , 2011, BMJ Case Reports.

[19]  J. Zwerina,et al.  Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis , 2011, Annals of the rheumatic diseases.

[20]  S. Reichenbach,et al.  Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. , 2011, Swiss medical weekly.

[21]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.

[22]  K. Hagihara,et al.  Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica , 2010, The Journal of Rheumatology.

[23]  M. López-Hoyos,et al.  Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. , 2008, Cytokine.

[24]  P. Merkel,et al.  Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. , 2007, Arthritis and rheumatism.

[25]  L. Mortelmans,et al.  Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. , 2006, Arthritis and rheumatism.

[26]  L. Cimino,et al.  Interleukin-6 promoter polymorphism at position -174 in giant cell arteritis. , 2005, The Journal of rheumatology.

[27]  H. Rubin,et al.  Domains of health-related quality of life important to patients with giant cell arteritis. , 2003, Arthritis and rheumatism.

[28]  S. Gabriel,et al.  Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. , 2003, Arthritis and rheumatism.

[29]  W. Thomson,et al.  IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. , 2002, Clinical and experimental rheumatology.

[30]  J. Fernandez-Solà,et al.  A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. , 2002, Arthritis and rheumatism.

[31]  A. Hajeer,et al.  Visual Manifestations of Giant Cell Arteritis: Trends and Clinical Spectrum in 161 Patients , 2000, Medicine.

[32]  E. Gromnica-ihle,et al.  Color duplex ultrasonography in the diagnosis of temporal arteritis. , 1997, The New England journal of medicine.

[33]  G. Hunder,et al.  Tissue Cytokine Patterns in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis , 1994, Annals of Internal Medicine.

[34]  G. Hunder,et al.  Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. , 1993, Arthritis and rheumatism.

[35]  L. A. Healey,et al.  Polymyalgia rheumatica and giant cell arteritis. , 1984, The Western journal of medicine.

[36]  P. Kieffer,et al.  [Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review]. , 2014, La Revue de medecine interne.

[37]  P. Kieffer,et al.  Efficacité clinique et biologique du tocilizumab au cours de la maladie de Horton : à propos de trois observations et revue de la littérature , 2013 .

[38]  A. Portier,et al.  Production of interleukin 6 by granulomas of giant cell arteritis. , 1994, Human immunology.